Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model

Ziritaxestat, an autotaxin inhibitor, was under development for the treatment of idiopathic pulmonary fibrosis. It is a substrate of cytochrome P450 3A4 (CYP3A4) and P‐glycoprotein and a weak inhibitor of the CYP3A4 and OATP1B1 pathways. We developed a physiologically based pharmacokinetic (PBPK) ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrier, Jeremy, Gualano, Virginie, Helmer, Eric, Namour, Florence, Lukacova, Viera, Taneja, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651654/
https://www.ncbi.nlm.nih.gov/pubmed/37667518
http://dx.doi.org/10.1111/cts.13622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651654/
https://www.ncbi.nlm.nih.gov/pubmed/37667518
http://dx.doi.org/10.1111/cts.13622

Ejemplares similares